Foghorn Therapeutics Inc. (FHTX)
Market Cap | 259.86M |
Revenue (ttm) | 34.16M |
Net Income (ttm) | -98.43M |
Shares Out | 42.57M |
EPS (ttm) | -2.34 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 59,032 |
Open | 6.26 |
Previous Close | 6.28 |
Day's Range | 6.26 - 6.78 |
52-Week Range | 2.70 - 9.97 |
Beta | 3.17 |
Analysts | Strong Buy |
Price Target | 14.50 (+116.1%) |
Earnings Date | Mar 7, 2024 |
About FHTX
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myel... [Read more]
Financial Performance
In 2023, FHTX's revenue was $34.16 million, an increase of 77.63% compared to the previous year's $19.23 million. Losses were -$98.43 million, -9.60% less than in 2022.
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for FHTX stock is "Strong Buy." The 12-month stock price forecast is $14.5, which is an increase of 116.10% from the latest price.
News
Foghorn to Host Conference Call and Webcast on Pipeline of Potential First-in-Class Medicines in Conjunction with the 2024 AACR Annual Meeting
Company management will review key pipeline programs, including an update on FHD-286 for AML, new preclinical data for the BRM selective inhibitor FHD-909 and for its selective CBP and EP300 degrader ...
Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlook
• Dose escalation in FHD-286 combination study in AML continues to progress; clinical data anticipated in the second half of 2024
Foghorn Therapeutics to Present New Preclinical Data at 2024 AACR Annual Meeting, Reflecting Advances with Multiple Potential First-in-Class Medicines, including the Selective Inhibitor of BRM, FHD-909
Poster presentation of FHD-909, a first-in-class oral BRM selective inhibitor, highlighting preclinical efficacy and safety in multiple mouse models of NSCLC; IND filing planned in Q2 2024
Foghorn Therapeutics to Participate in Cowen's 44th Annual Health Care Conference
CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by...
Foghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286, a Novel BRG1/BRM Inhibitor, in Patients with Advanced Hematologic Malignancies, to be Presented at American Society of Hematology Annual Meeting
CAMBRIDGE, Mass., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by...
Foghorn Therapeutics Provides Third Quarter 2023 Financial and Corporate Update
CAMBRIDGE, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by...
Foghorn Therapeutics Announces Clinical Data From Phase 1 Study of FHD-286 in Metastatic Uveal Melanoma to Be Presented at ESMO Congress
CAMBRIDGE, Mass., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by...
Foghorn Therapeutics to Present Clinical and Pre-Clinical Data from Multiple Programs Across Its Diverse Pipeline at AACR-NCI-EORTC International Conference
CAMBRIDGE, Mass., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by...
Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development Officer
CAMBRIDGE, Mass. , Sept. 11, 2023 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, announced today the appointment of Amanda Kay as Senior Partner and Chief Business Developmen...
Foghorn Therapeutics Announces First Patient Dosed in Phase 1 Combination Study of FHD-286 for Relapsed and/or Refractory AML
CAMBRIDGE, Mass., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious disease by ...
Foghorn Therapeutics Provides Second Quarter 2023 Financial and Corporate Update
— Initiating FHD-286 combination study in AML in the third quarter of 2023 — Selective BRM, ARID1B, EP300, and CBP, targeting key regulators of gene expression, continue to advance toward IND — Cash, ...
Foghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286 in Metastatic Uveal Melanoma
- Clinical data support safety and tolerability profile of FHD-286, a highly potent, - selective, allosteric, oral, small molecule inhibitor of BRG1/BRM - Clinical activity observed in late-line metas...
Flagship Pioneering Unveils Empress Therapeutics to Revolutionize Drug Discovery by Applying the Power of Genetics to Identify Small Molecule Drugs
Empress's Chemilogics™ product platform creates small molecule drugs quickly and cost-effectively The company emerges after two years of platform development with an initial commitment of $50 million ...
Foghorn Therapeutics Announces Participation in Upcoming Investor Conferences
CAMBRIDGE, Mass., June 07, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by...
Foghorn Therapeutics Announces FDA Has Lifted Clinical Hold on Phase 1 Study of FHD-286 in Relapsed and/or Refractory AML/MDS Patients
- Plan to Initiate a Phase 1 Study of FHD-286 in Combination with Decitabine or Cytarabine in Relapsed and/or Refractory AML Patients in Q3'2023
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTX
NEW YORK , May 10, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Foghorn Therapeutics Inc. ("Foghorn" or the "Company") (NASDAQ: FHTX). Such investors are advise...
Foghorn Therapeutics Provides First Quarter 2023 Financial and Corporate Update
CAMBRIDGE, Mass., May 08, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by ...
Foghorn Therapeutics to Participate at the H.C. Wainwright BioConnect Investor Conference
CAMBRIDGE, Mass., April 25, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases b...
Foghorn Therapeutics stock slides 21% after FDA puts partial clinical hold on cancer drug trial
Foghorn Therapeutics Inc.'s stock FHTX slid 21% in premarket trade Monday, after the biotech said the Food and Drug Administration has placed a partial hold on a cancer trial. The company is pausing e...
Foghorn Therapeutics Provides an Update on FHD-609
CAMBRIDGE, Mass., April 24, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases b...
Foghorn Therapeutics to Present Preclinical Data from Its Selective CBP and EP300 Protein Degrader Programs and Preclinical Data for FHD-286, a Potent, Selective Inhibitor of BRG1 and BRM, at the 2023 American Association for Cancer Research Annual Meeting
CAMBRIDGE, Mass., April 10, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases b...
Foghorn Therapeutics to Highlight Transcription Factor and Protein Degradation Capabilities at the 18th Annual Drug Discovery Chemistry Meeting
CAMBRIDGE, Mass., April 06, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases b...
Foghorn Therapeutics Provides 2023 Outlook and Full Year 2022 Corporate Update
- Phase 1 dose escalation study of FHD-286, a BRG1/BRM inhibitor, in metastatic uveal melanoma continues to progress with initial safety and efficacy data expected in the first half of 2023
Foghorn Therapeutics Announces New Preclinical Data for FHD-286 in AML to Be Presented at the American Society of Hematology Annual Meeting
CAMBRIDGE, Mass., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by...
Foghorn Therapeutics to Participate at the Evercore ISI HealthCONx Conference
CAMBRIDGE, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that treat serious diseases by...